Message #36 From:
NewsBot Date: October 26, 2006 05:25:00 AM
CYKN News Cyberkinetics to Present at the C.E. Unterberg, Towbin Life Sciences Conference
FOXBOROUGH, Mass.--(BUSINESS WIRE)--Cyberkinetics Neurotechnology Systems, Inc. (OTCBB: CYKN;
"Cyberkinetics"), announced that Timothy R. Surgenor, Cyberkinetics'
President and Chief Executive Officer, will present an overview of the
Company at the upcoming C.E. Unterberg Life Sciences Conference at 1:30
p.m. ET on Tuesday, October 31, 2006, in New York City. The conference
includes a diverse group of companies that will address the
opportunities and challenges for investors in life sciences technologies.
Interested parties can access a live audio webcast at the date and time
of the Company’s presentation through a link
at http://www.wsw.com/webcast/ceut5/cykn.ob/.
Cyberkinetics’ slide presentation and the
audio webcast will also be available via the Company’s
website at www.cyberkineticsinc.com
following the presentation.
About C.E. Unterberg, Towbin
C.E. Unterberg, Towbin provides investment banking research and
investment management services to emerging growth companies and
investors in the technology, healthcare, and global security sectors.
Originally established in 1932, Unterberg is headquartered in New
York, with offices in California
and Israel. A
relationship-driven bank, Unterberg is defined by its: industry focus; a
dedication to providing service by the senior members of the firm; its
respected research team; global reach and perspective; and a commitment
to serve the financial needs of tomorrow's industry leaders.
About Cyberkinetics Neurotechnology Systems, Inc.
Cyberkinetics Neurotechnology Systems, Inc., a leader in the
neurotechnology industry, is developing neural stimulation, sensing and
processing technology to improve the lives of those with severe
paralysis resulting from spinal cord injuries, neurological disorders
and other conditions of the nervous system. Cyberkinetics’
product development pipeline includes: the Andara™
Oscillating Field Stimulator (OFS™) Device, an
investigative device designed to stimulate regeneration of the neural
tissue surrounding the spinal cord; and the BrainGate System, an
investigative device designed to provide communication and control of a
computer, assistive devices, and, ultimately, limb movement; and the
NeuroPort™ System, a cleared-to-market neural
monitor designed for acute inpatient applications and labeled for
temporary (less than 30 days) recording and monitoring of brain
electrical activity. Additional Information is available at Cyberkinetics’
website at http://www.cyberkineticsinc.com.
Forward-Looking Statements
This announcement contains forward-looking statements, including
statements about Cyberkinetics' product development plans and progress,
potential development of proprietary inventions and benefits that may be
realized by certain research programs. These statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, and can be identified by the use of
forward-looking terminology such as "may," "will," "believe," "expect,"
"anticipate" or other comparable terminology. Forward-looking statements
involve risks and uncertainties that could cause actual results to
differ materially from those projected in forward-looking statements and
reported results shall not be considered an indication of our future
performance. Factors that might cause or contribute to such differences
include our limited operating history; our lack of profits from
operations; our ability to successfully develop and commercialize our
proposed products; a lengthy approval process and the uncertainty of FDA
and other governmental regulatory requirements; clinical trials may fail
to demonstrate the safety and effectiveness of our products; the degree
and nature of our competition; our ability to employ and retain
qualified employees; compliance with recent legislation regarding
corporate governance, including the Sarbanes-Oxley Act of 2002; as well
as those risks more fully discussed in our public filings with the
Securities and Exchange Commission, all of which are difficult to
predict and some of which are beyond our control.
